Nantong

Futó vizsgálatok

• Még nem toboroz

  A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

  NCT07816237· 3. fázis· Bisirna Therapeutics (Suzhou) Co., Ltd.· Forrás

  Contact: Charlene Si